ASB2 and acute myeloid leukemia: FTO downregulates m6A levels, modulates the expression of Ankyrin Repeat and SOCS Box Containing 2 (ASB2) and Retinoic Acid Receptor Alpha (RARA), enhances gene-mediated cell transformation and leukemia onset, and inhibits acute myeloid leukemia (AML) cell differentiation [9].